Cytogenetics News and Research

RSS

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology, published online an analysis of patient samples from the Intergroupe Francophone du Myéloma 2009 trial.

1 Oct 2018

Five microRNAs predict course, recurrence of HPV-negative head and neck cancer

A new method predicts the course of HPV-negative head and neck cancer after radiation chemotherapy.

4 Sep 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Study provides novel insights into evolutionary pathways of pancreatic cancer

Pancreatic cancer is a form of cancer associated with the highest mortality rates in the world. Genetic changes that could explain his aggressiveness and early metastasis had not been found yet.

30 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

Leica Biosystems agrees with the UK Office of Life Sciences to advance AI in pathology

A transformative sector deal was announced between companies of the UK life sciences sector and the UK government on Wednesday, December 6th, 2017. This agreement draws substantial investment into the sector including the development of a trail-blazing digital pathology program leveraging Artificial Intelligence.

22 Dec 2017

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

1 Sep 2017

CNIO researchers optimize new system capable of generating cellular model of Ewing sarcoma

A team from the Spanish National Cancer Research Centre (CNIO) has optimized a system capable of generating a cellular model of Ewing sarcoma.

10 May 2017

Breakthrough in cancer cell screening advances personalised treatment of childhood leukaemia

Researchers at Newcastle University have been able to accurately predict how children whose cancer returns after treatment for leukaemia are likely to respond to further treatment.

26 Aug 2016

Updated guidelines for breast cancer increase number of patients who test HER2-positive

Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology.

28 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Four miRNAs may hold vital clue to disease progression in gliobastoma

Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment.

14 Jun 2016

OGT launches Cytocell FISH probes for glial tumours

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours.

4 May 2016

Diversigen, Baylor Miraca to provide customers access to targeted genomics and metabolomics services

Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with Baylor Miraca Genetics Laboratories, a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services.

23 Feb 2016

NeoGenomics acquires Clarient and Clarient Diagnostic Services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc. Clarient, a provider of comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry, was a unit of GE Healthcare's Life Sciences business.

30 Dec 2015

Researchers identify new gene that helps maintain chromosome number in cells

Molecular biologists at UT Southwestern Medical Center have identified a gene called NORAD that helps maintain the proper number of chromosomes in cells, and that when inactivated, causes the number of chromosomes in a cell to become unstable, a key feature of cancer cells.

26 Dec 2015

Mitochondrial variation and viable pregnancy: an interview with Dr Elpida Fragouli

Embryos require adequate amounts of energy so that they can successfully progress through each of their cell divisions.

16 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015